Trade ALX Oncology Holdings Inc. - ALXO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 4.83 |
| Open* | 4.78 |
| 1-Year Change* | -74.08% |
| Day's Range* | 4.56 - 4.84 |
| 52 wk Range | 4.52-19.85 |
| Average Volume (10 days) | 429.94K |
| Average Volume (3 months) | 4.73M |
| Market Cap | 195.63M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 40.86M |
| Revenue | N/A |
| EPS | -3.03 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | May 8, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 23, 2023 | 4.83 | 0.29 | 6.39% | 4.54 | 4.87 | 4.54 |
| Mar 22, 2023 | 4.78 | -0.04 | -0.83% | 4.82 | 4.95 | 4.63 |
| Mar 21, 2023 | 4.79 | 0.09 | 1.91% | 4.70 | 5.02 | 4.68 |
| Mar 20, 2023 | 4.60 | -0.16 | -3.36% | 4.76 | 4.78 | 4.49 |
| Mar 17, 2023 | 4.76 | -0.15 | -3.05% | 4.91 | 4.95 | 4.63 |
| Mar 16, 2023 | 4.98 | -0.08 | -1.58% | 5.06 | 5.13 | 4.92 |
| Mar 15, 2023 | 5.17 | 0.09 | 1.77% | 5.08 | 5.38 | 4.67 |
| Mar 14, 2023 | 5.23 | -0.49 | -8.57% | 5.72 | 5.74 | 5.07 |
| Mar 13, 2023 | 5.60 | 0.42 | 8.11% | 5.18 | 5.90 | 5.18 |
| Mar 10, 2023 | 5.36 | -0.33 | -5.80% | 5.69 | 5.73 | 5.02 |
| Mar 9, 2023 | 5.84 | -0.27 | -4.42% | 6.11 | 6.19 | 5.60 |
| Mar 8, 2023 | 6.21 | -0.16 | -2.51% | 6.37 | 6.39 | 6.11 |
| Mar 7, 2023 | 6.37 | 0.07 | 1.11% | 6.30 | 6.54 | 6.29 |
| Mar 6, 2023 | 6.44 | -0.04 | -0.62% | 6.48 | 6.48 | 6.20 |
| Mar 3, 2023 | 6.50 | 0.19 | 3.01% | 6.31 | 6.67 | 6.31 |
| Mar 2, 2023 | 6.45 | 0.11 | 1.74% | 6.34 | 6.47 | 6.23 |
| Mar 1, 2023 | 6.48 | 0.04 | 0.62% | 6.44 | 6.60 | 6.43 |
| Feb 28, 2023 | 6.59 | 0.16 | 2.49% | 6.43 | 6.66 | 6.43 |
| Feb 27, 2023 | 6.63 | 0.15 | 2.31% | 6.48 | 6.74 | 6.48 |
| Feb 24, 2023 | 6.54 | -0.30 | -4.39% | 6.84 | 6.84 | 6.39 |
ALX Oncology Holdings Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total revenue | 0 | 1.182 | 4.796 | 2.067 |
| Revenue | 0 | 1.182 | 4.796 | 2.067 |
| Cost of Revenue, Total | 1.075 | 4.36 | 1.88 | |
| Gross Profit | 0.107 | 0.436 | 0.187 | |
| Total Operating Expense | 83.555 | 45.466 | 23.979 | 15.751 |
| Selling/General/Admin. Expenses, Total | 23.385 | 14.809 | 3.313 | 2.601 |
| Research & Development | 60.17 | 28.961 | 16.306 | 11.27 |
| Operating Income | -83.555 | -44.284 | -19.183 | -13.684 |
| Interest Income (Expense), Net Non-Operating | -0.013 | -0.811 | -0.021 | 0 |
| Other, Net | 0.084 | -0.404 | -0.005 | -0.002 |
| Net Income Before Taxes | -83.484 | -45.499 | -19.209 | -13.686 |
| Net Income After Taxes | -83.463 | -45.74 | -19.243 | -13.731 |
| Net Income Before Extra. Items | -83.463 | -45.74 | -19.243 | -13.731 |
| Net Income | -83.463 | -45.74 | -19.243 | -13.731 |
| Total Adjustments to Net Income | 0 | -5.202 | -4.028 | -3.671 |
| Income Available to Common Excl. Extra. Items | -83.463 | -50.942 | -23.271 | -17.402 |
| Income Available to Common Incl. Extra. Items | -83.463 | -50.942 | -23.271 | -17.402 |
| Diluted Net Income | -83.463 | -50.942 | -23.271 | -17.402 |
| Diluted Weighted Average Shares | 40.308 | 18.4853 | 34.7116 | 34.7116 |
| Diluted EPS Excluding Extraordinary Items | -2.07063 | -2.7558 | -0.67041 | -0.50133 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Diluted Normalized EPS | -2.07063 | -2.73397 | -0.67041 | -0.50133 |
| Unusual Expense (Income) | 0 | 0.621 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | |
| Total Operating Expense | 24.747 | 28.472 | 24.576 | 16.299 | 14.208 |
| Selling/General/Admin. Expenses, Total | 7.674 | 7.578 | 6.362 | 5.086 | 4.359 |
| Research & Development | 17.073 | 20.894 | 18.214 | 11.213 | 9.849 |
| Operating Income | -24.747 | -28.472 | -24.576 | -16.299 | -14.208 |
| Interest Income (Expense), Net Non-Operating | 0.225 | -0.003 | -0.004 | -0.003 | -0.003 |
| Other, Net | -0.011 | 0.016 | 0.014 | 0.028 | 0.026 |
| Net Income Before Taxes | -24.533 | -28.459 | -24.566 | -16.274 | -14.185 |
| Net Income After Taxes | -24.533 | -28.438 | -24.566 | -16.274 | -14.185 |
| Net Income Before Extra. Items | -24.533 | -28.438 | -24.566 | -16.274 | -14.185 |
| Net Income | -24.533 | -28.438 | -24.566 | -16.274 | -14.185 |
| Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
| Income Available to Common Excl. Extra. Items | -24.533 | -28.438 | -24.566 | -16.274 | -14.185 |
| Income Available to Common Incl. Extra. Items | -24.533 | -28.438 | -24.566 | -16.274 | -14.185 |
| Diluted Net Income | -24.533 | -28.438 | -24.566 | -16.274 | -14.185 |
| Diluted Weighted Average Shares | 40.6163 | 40.5297 | 40.3962 | 40.2471 | 40.0554 |
| Diluted EPS Excluding Extraordinary Items | -0.60402 | -0.70166 | -0.60813 | -0.40435 | -0.35413 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.60402 | -0.70166 | -0.60813 | -0.40435 | -0.35413 |
| Cost of Revenue, Total | 0 | 0 | |||
| Gross Profit | 0 | 0 | |||
| Unusual Expense (Income) | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total Current Assets | 367.019 | 435.992 | 9.809 | 10.208 |
| Cash and Short Term Investments | 363.667 | 434.219 | 9.017 | 8.262 |
| Cash | 434.219 | 9.017 | 8.262 | |
| Total Receivables, Net | 0 | 0.536 | 0.932 | |
| Accounts Receivable - Trade, Net | 0 | 0.536 | 0.932 | |
| Prepaid Expenses | 3.352 | 1.773 | 0.256 | 1.014 |
| Total Assets | 380.183 | 436.054 | 10.676 | 11.164 |
| Property/Plant/Equipment, Total - Net | 3.397 | 0.052 | 0.86 | 0.956 |
| Property/Plant/Equipment, Total - Gross | 3.46 | 0.077 | 2.309 | 1.976 |
| Accumulated Depreciation, Total | -0.063 | -0.025 | -1.449 | -1.02 |
| Other Long Term Assets, Total | 9.767 | 0.01 | 0.007 | 0 |
| Total Current Liabilities | 15.295 | 6.204 | 4.984 | 1.873 |
| Accounts Payable | 3.764 | 0.004 | 3.748 | 0.697 |
| Accrued Expenses | 11.102 | 6.049 | 1.046 | 0.905 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.151 | 0.19 | 0.271 | |
| Total Liabilities | 17.134 | 6.209 | 10.952 | 2.009 |
| Total Long Term Debt | 0.28 | 0 | 5.421 | 0 |
| Long Term Debt | 5.421 | 0 | ||
| Other Liabilities, Total | 1.559 | 0.005 | 0.547 | 0.136 |
| Total Equity | 363.049 | 429.845 | -0.276 | 9.155 |
| Preferred Stock - Non Redeemable, Net | 70.363 | 60.933 | ||
| Common Stock | 0.041 | 0.04 | 0.021 | 0.021 |
| Additional Paid-In Capital | 564.993 | 548.327 | 2.122 | 1.74 |
| Retained Earnings (Accumulated Deficit) | -201.985 | -118.522 | -72.782 | -53.539 |
| Total Liabilities & Shareholders’ Equity | 380.183 | 436.054 | 10.676 | 11.164 |
| Total Common Shares Outstanding | 40.5871 | 39.8445 | 34.7116 | 34.7116 |
| Redeemable Preferred Stock | 0 | |||
| Cash & Equivalents | 363.667 | |||
| Current Port. of LT Debt/Capital Leases | 0.429 | |||
| Capital Lease Obligations | 0.28 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 321.525 | 367.019 | 388.963 | 412.277 | 432.327 |
| Cash and Short Term Investments | 316.596 | 363.667 | 385.149 | 409.964 | 429.855 |
| Cash & Equivalents | 159.086 | 363.667 | 385.149 | 409.964 | 429.855 |
| Prepaid Expenses | 4.929 | 3.352 | 3.814 | 2.313 | 2.472 |
| Total Assets | 363.676 | 380.183 | 399.728 | 421.289 | 432.91 |
| Property/Plant/Equipment, Total - Net | 6.967 | 3.397 | 3.362 | 0.167 | 0.047 |
| Property/Plant/Equipment, Total - Gross | 7.088 | 3.46 | 3.401 | 0.2 | 0.077 |
| Accumulated Depreciation, Total | -0.121 | -0.063 | -0.039 | -0.033 | -0.03 |
| Other Long Term Assets, Total | 10.075 | 9.767 | 7.403 | 8.845 | 0.536 |
| Total Current Liabilities | 15.308 | 15.295 | 12.488 | 13.979 | 14.129 |
| Accounts Payable | 5.133 | 3.764 | 3.683 | 5.806 | 7.35 |
| Accrued Expenses | 9.746 | 11.102 | 8.376 | 7.744 | 2.735 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.429 | 0.429 | 0.429 | 0.429 | 0.095 |
| Other Current Liabilities, Total | 3.949 | ||||
| Total Liabilities | 20.08 | 17.134 | 14.556 | 16.275 | 14.426 |
| Total Long Term Debt | 0.175 | 0.28 | 0.385 | 0.489 | 0.131 |
| Capital Lease Obligations | 0.175 | 0.28 | 0.385 | 0.489 | 0.131 |
| Other Liabilities, Total | 4.597 | 1.559 | 1.683 | 1.807 | 0.166 |
| Total Equity | 343.596 | 363.049 | 385.172 | 405.014 | 418.484 |
| Redeemable Preferred Stock | 0 | ||||
| Common Stock | 0.041 | 0.041 | 0.04 | 0.04 | 0.04 |
| Additional Paid-In Capital | 570.679 | 564.993 | 558.679 | 553.955 | 551.151 |
| Retained Earnings (Accumulated Deficit) | -226.518 | -201.985 | -173.547 | -148.981 | -132.707 |
| Total Liabilities & Shareholders’ Equity | 363.676 | 380.183 | 399.728 | 421.289 | 432.91 |
| Total Common Shares Outstanding | 40.6566 | 40.5871 | 40.4863 | 40.3253 | 40.2086 |
| Short Term Investments | 157.51 | ||||
| Long Term Investments | 25.109 | ||||
| Other Equity, Total | -0.606 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Net income/Starting Line | -83.463 | -45.74 | -19.243 | -13.731 |
| Cash From Operating Activities | -68.101 | -38.289 | -14.249 | -13.19 |
| Cash From Operating Activities | 0.051 | 0.202 | 0.429 | 0.431 |
| Non-Cash Items | 19.338 | 7.002 | 0.308 | 0.269 |
| Changes in Working Capital | -4.027 | 0.247 | 4.257 | -0.159 |
| Cash From Investing Activities | -4.923 | 0.61 | -0.353 | -0.653 |
| Capital Expenditures | -4.923 | -0.031 | -0.353 | -0.653 |
| Cash From Financing Activities | 2.472 | 462.881 | 15.357 | 0.001 |
| Issuance (Retirement) of Stock, Net | 2.753 | 473.235 | 9.44 | 0.001 |
| Issuance (Retirement) of Debt, Net | -0.281 | 0 | 5.917 | 0 |
| Net Change in Cash | -70.552 | 425.202 | 0.755 | -13.842 |
| Cash Taxes Paid | 0.274 | 0.047 | ||
| Cash Interest Paid | 0.011 | 0.427 | ||
| Other Investing Cash Flow Items, Total | 0.641 | |||
| Financing Cash Flow Items | -10.354 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -24.533 | -83.463 | -55.025 | -30.459 | -14.185 |
| Cash From Operating Activities | -20.674 | -68.101 | -50.613 | -25.757 | -5.135 |
| Cash From Operating Activities | 0.058 | 0.051 | 0.017 | 0.011 | 0.005 |
| Non-Cash Items | 5.926 | 19.338 | 8.688 | 4.241 | 1.858 |
| Cash Interest Paid | 0 | 0.011 | 0.007 | 0.003 | 0 |
| Changes in Working Capital | -2.125 | -4.027 | -4.293 | 0.45 | 7.187 |
| Cash From Investing Activities | -183.921 | -4.923 | -0.405 | -0.007 | -0.007 |
| Capital Expenditures | -0.589 | -4.923 | -0.405 | -0.007 | -0.007 |
| Cash From Financing Activities | 0.08 | 2.472 | 1.948 | 1.509 | 0.778 |
| Issuance (Retirement) of Stock, Net | 0.185 | 2.753 | 2.125 | 1.582 | 0.778 |
| Net Change in Cash | -204.515 | -70.552 | -49.07 | -24.255 | -4.364 |
| Cash Taxes Paid | 0 | 0.274 | 0.274 | 0.274 | |
| Financing Cash Flow Items | 0 | 0 | |||
| Issuance (Retirement) of Debt, Net | -0.105 | -0.281 | -0.177 | -0.073 | |
| Other Investing Cash Flow Items, Total | -183.332 | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| VenBio Partners LLC | Private Equity | 23.8003 | 9699925 | 0 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 14.9987 | 6112789 | 1482504 | 2022-12-31 | LOW |
| Lightstone Ventures, L.P. | Investment Advisor | 11.1076 | 4526963 | -194027 | 2022-03-31 | LOW |
| Vivo Capital, LLC | Venture Capital | 10.3546 | 4220048 | 0 | 2022-12-31 | MED |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 7.0445 | 2871000 | 0 | 2022-12-31 | LOW |
| Logos Global Management LLC | Investment Advisor | 5.7651 | 2349600 | -621752 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.7051 | 1510050 | 40991 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.4941 | 1424043 | 14289 | 2022-12-31 | LOW |
| Eventide Asset Management, LLC | Investment Advisor | 2.2132 | 902000 | 0 | 2022-12-31 | MED |
| Cormorant Asset Management, LP | Hedge Fund | 1.5018 | 612079 | -100000 | 2022-12-31 | MED |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 1.4905 | 607470 | -144627 | 2022-12-31 | LOW |
| Pons (Jaume) | Individual Investor | 1.3244 | 539746 | -3232 | 2022-12-29 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.2268 | 500000 | 0 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 1.171 | 477236 | 90049 | 2022-12-31 | MED |
| Federated Hermes MDTA LLC | Investment Advisor/Hedge Fund | 1.1386 | 464029 | -685 | 2022-12-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0117 | 412309 | 18988 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.9656 | 393550 | 8987 | 2022-12-31 | LOW |
| DWS Investments UK Limited | Investment Advisor | 0.84 | 342355 | 142 | 2022-12-31 | MED |
| Pier Capital, LLC | Investment Advisor | 0.667 | 271848 | -769 | 2022-12-31 | MED |
| Randolph (Sophia) | Individual Investor | 0.6631 | 270253 | 44857 | 2022-12-29 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
ALX Oncology Holdings Inc. Company profile
About ALX Oncology Holdings Inc
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, ALX148, is a CD47 blocking therapeutic. ALX148 is a fusion protein that combines a CD47 binding domain with its inactivated fragment crystallizable (Fc) domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of signal regulatory protein alpha (SIRPa), a protein that is the natural receptor to CD47 found on myeloid cells. Its programs are focused on targeting CD47 across various oncology indications.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, ALX Oncology Holdings Inc revenues decreased from $1.2M to $0K. Net loss applicable to common stockholders increased 64% to $83.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Reserach and developement increase of 76% to $46.5M (expense).
| Industry: | Bio Therapeutic Drugs |
323 Allerton Avenue
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Income Statement
- Annual
- Quarterly
News
GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com